Moderna Inc (NASDAQ:MRNA) price on current trading day, fall -1.45% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $33.32.
A look at the stock’s price movement, the close in the last trading session was $33.81, moving within a range at $33.12 and $33.85. The beta value (5-Year monthly) was 1.862. Turning to its 52-week performance, $170.47 and $29.25 were the 52-week high and 52-week low respectively. Overall, MRNA moved -6.80% over the past month.
Moderna Inc’s market cap currently stands at around $12.86 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-13.
Analysts have a consensus estimate of 134.65M for the company’s revenue for the quarter, with a low and high estimate of 93.9M and 183M respectively. The average forecast suggests down to a -19.37% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 2.17B, representing a -32.93% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MRNA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
17 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 12 recommend MRNA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MRNA’s current price about -1.03% and -6.87% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.29, while 7-day volatility ratio is 5.33% and 6.81% in the 30-day chart. Further, Moderna Inc (MRNA) has a beta value of 2.14, and an average true range (ATR) of 2.37. Analysts have given the company’s stock an average 52-week price target of $55, forecast between a low of $45 and high of $69. Looking at the price targets, the low is -35.05% off current price level while to achieve the yearly target high, price needs to move -107.08%. Nonetheless, investors will most likely welcome a -65.07% jump to $55 which is the analysts’ median price.
If we refocus on Moderna Inc (NASDAQ:MRNA), historical trading data shows that trading volumes averaged 9.64 over the past 10 days and 11.74 million over the past 3 months. The company’s latest data on shares outstanding shows there are 386.00 million shares.
The 11.44% of Moderna Inc’s shares are in the hands of company insiders while institutional holders own 70.77% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 45.06 million on 2025-02-28, giving us a short ratio of 3.6. The data shows that as of 2025-02-28 short interest in Moderna Inc (MRNA) stood at 1535.0 of shares outstanding, with shares short rising to 40.6 million registered in 2025-01-31. Current price change has pushed the stock -19.87% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MRNA stock continues to rise going into the next quarter.
